论文部分内容阅读
糖尿病(Diabetes)是困扰人们的主要疾病之一,因其多发性和危害性受到高度重视。黄连素(Berberine,BBR)是一种从黄连等植物中提取的化合物,有很好的抗菌、抗炎症、抗肿瘤作用。但其治疗糖尿病的作用一直被忽视。最近G蛋白偶联受体GPR40已被确定为是黄连素的受体。然而,黄连素作为GPR40的配体的信号通路还没有被系统的研究或应用到糖尿病临床药物开发中。因此,我们通过药物抑制和蛋白免疫印迹的方法,首次研究黄连素介导GPR40激活ERK1/2信号通路的详细机制。本研究有助于为糖尿病的治疗提供新的思路和新的治疗方法。
Diabetes is one of the major diseases that plague people because of its high incidence and danger. Berberine (BBR) is a compound extracted from Coptis and other plants, has good antibacterial, anti-inflammatory, anti-tumor effect. But its role in the treatment of diabetes has been neglected. Recently G-protein coupled receptor GPR40 has been identified as a receptor for berberine. However, the signaling pathway of berberine as a ligand for GPR40 has not been systematically studied or applied to the development of clinical drugs for diabetes. Thus, for the first time, we investigated the detailed mechanism by which berberine mediates the activation of the ERK1 / 2 pathway by GPR40 through drug inhibition and Western blotting. This study helps to provide new ideas and new treatments for the treatment of diabetes.